Pembrolizumab + Cabozantinib
Phase 1/2Terminated 0 views this week 0 watching💤 Quiet
Interest: 14/100
14
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Clear Cell RCC
Conditions
Clear Cell RCC
Trial Timeline
Oct 22, 2024 → Jan 23, 2026
NCT ID
NCT06716853About Pembrolizumab + Cabozantinib
Pembrolizumab + Cabozantinib is a phase 1/2 stage product being developed by Genenta Science for Clear Cell RCC. The current trial status is terminated. This product is registered under clinical trial identifier NCT06716853. Target conditions include Clear Cell RCC.
What happened to similar drugs?
3 of 13 similar drugs in Clear Cell RCC were approved
Approved (3) Terminated (1) Active (9)
✅nebulized albuterol (2.5 mg/3ml/dose) + nebulized levalbuterol (1.25 mg/3ml/dose) + nebulized placebo (3ml/dose)Sumitomo PharmaApproved
Hype Score Breakdown
Clinical
9
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06716853 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Clear Cell RCC